A randomized, double-blind, multicentre, multinational comparative clinical study to compare the efficacy and safety of INTP24 against Avastin in patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer
Latest Information Update: 04 Mar 2020
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
Most Recent Events
- 31 Jan 2020 New trial record